×

Competing for a cure: Sarepta Therapeutics CEO

3:28 PM ET Fri, 13 Nov 2015

Ed Kaye, Sarepta Therapeutics Interim CEO, discusses what will happen if his drug for Duchenne muscular dystrophy gets approved and his strategy for working toward a cure.